Eye health

#Drug discovery #Eye health #Genetics #Inherited blindness

Gene linked to inherited blindness discovered

Faults in a gene known for causing a devastating childhood metabolic illness can also cause a form of inherited blindness in adults, an international study co-led by scientists at the University of Manchester, University College London and the Greenwood Genetic Center in the US has found. In the first study… Read More

#News

#Cell therapy #Eye health #Opthalmology

Are cell therapies the answer to age-related eye diseases?

In March 2026, Lineage Cell Therapeutics launched a new cell therapy programme for the treatment of corneal endothelial disease. Diana Turner caught up with Brian Culley, CEO of Lineage Cell Therapeutics, to find out more.  DT: How do you hope your in-house AlloSCOPE platform can overcome the problems and  practical hurdles associated with other cell… Read More

#Exclusive Content

Diabetic eye disease
#Clinical trial #Eye health #FDA

FDA approves thyroid eye disease treatment 

The US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) as a treatment for thyroid eye disease (TED).  TED is a rare, debilitating autoimmune disease characterised by inflammation and tissue remodelling around and behind the eyes, which can lead to proptosis, diplopia, pain and vision impairment.  Lumvoa was approved… Read More

#News #Regulatory

#Eye health #Immunology / Virology & Vaccines #LIfT BioSciences #mRNA

New DDW Highlights podcast: 11 August 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the week that the US… Read More

#News

Eye
#Cancer research #Eye health #iOnctura

Phase II study in metastatic uveal melanoma commences

iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has dosed the first patient in the randomised Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye. Roginolisib is an orally dosed small molecule allosteric modulator of PI3Kδ. Read More

#Cancer Research #News

#AAV #Clinical trials #Eye health #Gene therapy #Stargardt disease

First patient dosed in gene therapy study for Stargardt disease

SpliceBio has dosed the first patient in the Phase I/II ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector, for the treatment of Stargardt disease. Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene. It is the most common form of juvenile macular degeneration,… Read More

#News

Eye
#Eye health #FDA #Neuropathic corneal pain #OKYO Pharma

Neuropathic corneal pain treatment filed with FDA

OKYO Pharma, a clinical-stage biopharmaceutical company developing therapies for the treatment of neuropathic corneal pain and inflammatory dry eye disease has filed an application for Fast Track designation with the US Food and Drug Administration (FDA) for urcosimod (formerly known as OK-101). The company intends to use urcosimod for the… Read More

#News

Patient receiving eye drops
#Antibiotic resistance #Antibiotics #Eye health #NTC #Phase II trial

Antibiotic/NSAID combo shows potential for bacterial conjunctivitis

NTC has shared positive results from the Phase II MIRAKLE study evaluating the efficacy and tolerability of NTC014 (quinolone antibiotic + NSAID in eye drops solution) in the treatment of bacterial conjunctivitis in adults.  The results show the non-inferiority of NTC014 eye drops vs. antibiotic alone in… Read More

#News

#Biopharmaceuticals #Clinical trials #Diabetes #Diabetic macular oedema #Eye health #Retinopathy

Investigating potential for an oral treatment in diabetic retinopathy  

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO).  Breye is developing novel, oral ophthalmology drugs fordiabetic retinopathy (DR)… Read More

#News

Eye health ophthalmology
#Clinical trials #Diabetes #Exonate #Eye health #mRNA #Ophthalmology #Small molecules

Trial in diabetic macular oedema successfully completed  

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study.   During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity. Exonate… Read More

#News

Diabetic eye disease
#Diabetes #Eye health #John Hopkins Medicine #Ophthalmology #Preclinical development

Experimental drug could prevent diabetic eye disease

New study results show that an experimental drug may prevent or slow vision loss in people with diabetes. The researchers at Wilmer Eye Institute, Johns Hopkins Medicine used mouse as well as human retinal organoids and eye cell lines in their investigations. Eye conditions… Read More

#Editor's Choice #News

Eye
#Clinical trials #Comment #Covid-19 #Eye #Eye health #Ophthalmology

New narrated podcast on ophthalmology

This is the latest episode of the free DDW podcast, “A deep dive into the future of ophthalmology”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Innovation, investment and commitment: Genentech’s approach to the future of ophthalmology” and “… Read More

#News

#Drug discovery #Eye health #iPSC #Ophthalmology #Partnership

Evotec enters ophthalmology drug discovery partnership 

Evotec has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (iPSC)-based disease modelling for ophthalmologic disorders.   Context   Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions. … Read More

#News

Human eye
#Clinical trials #Comment #Covid-19 #Eye health

Innovative delivery: sustained ophthalmic steroids in diabetic macular edema 

Listen to this article on the DDW Podcast: Professor Sobha Sivaprasad, Professor of Retinal Clinical Studies, UCL Institute of Ophthalmology, and Consultant Ophthalmologist, Moorfields Eye Hospital, UK discusses unmet needs in DME therapeutics and how they could be addressed by sustained release ophthalmic steroids administered with novel suprachoroidal drug delivery methods.  Diabetic eye… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

Patient receiving eye drops
#Clinical trials #Eye health #Healthcare #Therapeutics

Stuart Therapeutics Phase II clinical trial results of its dry eye candidate  

Stuart Therapeutics, a clinical stage, ophthalmic therapeutic development company, has announced the topline results of the first in human Phase II clinical trial for its lead drug candidate, ST-100 in patients with dry eye disease.   The trial  The clinical trial, conducted between June and October… Read More

#News